NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Sociedad Española de Neumología y Cirugía Torácica.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Spanish Research Center for Respiratory Diseases
Information provided by:
Sociedad Española de Neumología y Cirugía Torácica
ClinicalTrials.gov Identifier:
NCT01141829
First received: June 10, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

June 10, 2010
June 10, 2010
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)
NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is associated with increased oxidative stress. The major sources of Reactive Oxygen Species (ROS) in the vasculature are the NADPH oxidases. Several polymorphisms related to NADPH oxidase expression or NADPH oxidase activity has been identified. The investigators are going to compare the distribution of the allelic frequencies of A-930G and C242T polymorphisms and their possible relationship with the levels of 8-isoprostanes as a marker of oxidative stress in patients with OSA and in a control group without OSA.

DESIGN: CASE-CONTROL STUDY METHODS: We are going to determine the A-930G and C242T p22phox genotypes in patients with OSA and healthy subjects recruited from sleep unit of Son Dureta University Hospital, (Palma de Mallorca, Spain). 8-Isoprostane is going to be measured as an oxidative stress marker with an 8-isoprostane EIA kit (Cayman Chemicals Company, USA) in plasma samples.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

patients with OSAS defined by an apnea hypopnea index (AHI)>10 h-1 will be included in the study along with control subjects without OSAS. Participants were consequently studied at the sleep unit of Hospital Universitario Son Dureta, (Palma de Mallorca, Spain).

  • Sleep Apnea Syndrome
  • Oxidative Stress
  • Single Nucleotide Polymorphism
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:Polyysomnografic study with Apnoea/Hypoapnoea Index higher to 10 in patients and lower in controls.

Exclusion Criteria:

  • chronic obstructive pulmonary disease, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure and/or psychiatric disorders.
Both
18 Years and older
Yes
Contact: Mónica de La Peña, MD 0034971175112 monica.delapena@ssib.es
Spain
 
NCT01141829
NADPHPM2010
No
Javier Piérola Lopetegui, Hospital Universitario Son Dureta
Sociedad Española de Neumología y Cirugía Torácica
Spanish Research Center for Respiratory Diseases
Not Provided
Sociedad Española de Neumología y Cirugía Torácica
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP